Philips subsidiary to pay over $24 million for alleged false claims for medical equipment By Reuters
Economy 12 minutes ago (Sep 01, 2022 20:11)
© Reuters. FILE PHOTO: Dutch technology company Philips logo is seen at company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier
WASHINGTON (Reuters) – A subsidiary of Dutch medical device maker Philips has agreed to pay over $24 million to resolve alleged false claims over respiratory-related medical equipment, the U.S. Justice Department said on Thursday.
The subsidiary, Philips RS North America LLC, formerly known as Respironics Inc, resolved allegations that it misled federal health care programs by paying kickbacks to durable medical equipment suppliers, the Justice Department said in a statement.
Philips subsidiary to pay over $24 million for alleged false claims for medical equipment
(Bloomberg) — Say you had a crystal ball, and could see today what the jobs report will show tomorrow. Would you even know how to trade it?
Never a simple proposition, it’s an…
(Bloomberg) — Wall Street is on edge as it heads into a dangerous final few months of 2022 with the Federal Reserve set to keep raising interest rates and the calendar flipping to…
By Sheila Dang (Reuters) -Twitter Inc will launch a widely requested edit button for its paid subscribers in the coming weeks, the social media company said Thursday. For years,…
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.